Six-Gene Immune Signature for Head and Neck Cancer Prognosis

A six-gene immune-related signature stratifies prognosis and characterizes the tumor immune microenvironment in head and neck squamous cell carcinoma. Pian Li developed this signature by integrating transcriptomic and clinical data from TCGA and GEO cohorts, publishing it in April 2026. The 23.8 KB Excel file contains the derived prognostic model and its validation results.

Use Cases

• Stratify patients into high- and low-risk groups using the six-gene signature (PYGL, SFRP1, FGD3, OLR1, DUSP9, MASP1).
• Correlate signature risk scores with immune infiltration levels and tumor mutation burden (TMB) metrics.
• Assess the signature's performance in predicting response to immune checkpoint blockade therapy across validation cohorts.
• Investigate the functional role of specific genes like PYGL in cancer cell proliferation and migration via associated knockdown results.

Strengths

• Signature validated across four independent cohorts (TCGA and GEO).
• Model built using Cox and LASSO regression on integrated transcriptomic and clinical data.

Limitations

• Dataset is very small (23.8 KB), indicating limited raw data, likely containing only model results.
• Unknown row count and specific column structure limit direct analytical reuse.

Provenance

Source

Integrated data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO).

Collection Method

Transcriptomic and clinical data integration, unsupervised clustering, and regression modeling.

Freshness

Last updated April 2026.